Ormco Unveils A Refreshed Brand Identity While Staying True to Core Values

With over 60 years of distinguished history in providing the orthodontic community with a breadth of high-quality, innovative products, solutions, and education, Ormco announces a brand refresh inspired by its recommitment as an innovative partner to the orthodontic community. With a continual dedication to partnership, investment in doctor-inspired innovation, and greater clinical freedom, the company will share its new company tagline, “Driving the future of orthodontics, together” along with the unveiling of a visually refreshed brand identity at this year’s American Association of Orthodontists (AAO) in Chicago, Illinois April 21-24, 2023.

Initial elements of Ormco’s brand refresh include:

New Company Tagline: “Driving the future of orthodontics, together”

New Logo: As a prominent representation of the company and its dedication, the new logo incorporates “Together” as a recommitment to collaboration and doctor-inspired innovation.

New Brand Colors: Fresh new colors convey passion and bring to life Ormco’s commitment, dedication, innovation, and future-focused partnership for all orthodontic solutions.

“In the spirit of a brand refresh, we continue to recognize and respect the expertise of orthodontic specialists as well as their investment in advancing their education, building a vision for their practices, and growing their businesses, all while helping patients enjoy healthier beautiful smiles,” said Eric Conley, SVP Orthodontics for Envista. “The renewed commitment to our existing and new customers is to provide best-in-class products, doctor-inspired innovation, and clinical freedom by giving the flexibility to choose orthodontic solutions and preferences that best fit their practices,” he continued.

As part of its commitment to driving the future of orthodontics, Ormco continually invests in doctor-inspired innovations. Ormco has more than 1000 patents worldwide and invests millions annually in Research & Development to ensure its products continue to respond to the evolving needs of orthodontists and patients.

“By investing in innovation, Ormco is also investing in me. It’s a symbiotic partnership. We make Ormco better, and Ormco makes us better,” said Dr. Trevor Nichols of Frost Nichols Orthodontics.

“Ormco also invests in the success of orthodontists through industry-leading partnership,” said Dr. Stuart Frost of Frost Nichols Orthodontics. “As the single, trusted, and proven partner for orthodontic specialists, Ormco helps simplify vendor management so we can focus on growing our practice. We turn to Ormco as our one source for complete orthodontic needs, as well as robust educational offerings, a dedicated support team, marketing resources, a generous loyalty program, and expert-led events to keep us at the forefront of our profession,” Dr. Frost continued.

The significant investment in R&D has led to a number of industry-first and breakthrough products and features including:

  • The first true full expression system designed for faster and more precise finishing with the Damon Ultima™ System.1
  • The new Ultima™ Hook, the only repositionable hook.2
  • Proprietary ceramic bracket technology and advanced clear bracket design with Symetri™ Clear
  • TruRoot™ for Spark™ Clear Aligners that allow doctors to see actual roots in the treatment plan
  • Ormco’s new OrthoPulse® 2.0 light-powered treatment accelerator that applies low-intensity infrared technology for up to 50% faster treatment time3 and a 73% reduction in pain4

Along with the Damon Ultima System for self-ligation, Ormco’s portfolio includes the Spark TM Clear Aligner System, Titanium Orthos TM, Symetri TM Clear, AOA Lab, Mini Twin TM, and OrthoPulse® Light Accelerated OrthodonticsTM*. In addition, as part of the Envista family of companies, Ormco provides doctors with Dexis™ IS scanning solutions and Metrex™ infection prevention solutions. With a portfolio encompassing wire and bracket systems, clear aligners, light accelerated technologies, 2D and 3D imaging, infection prevention, custom appliances, and more — Ormco provides a full gamut of innovations that help doctors improve patients’ smiles by leveraging the future of orthodontics.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”